Document:

Exhibit 10.1

 

TENDER AND SUPPORT AGREEMENT

 

This
Tender and Support Agreement (this “Agreement”) is entered into as of October 11, 2021, by and among Pacira
BioSciences, Inc., a Delaware corporation (“Parent”), Oyster Acquisition Company Inc., a Delaware corporation
and a wholly owned subsidiary of Parent (“Purchaser”), and [●] (“Stockholder”).

 

Recitals

 

A.            Stockholder
is a holder of record and the “beneficial owner” (within the meaning of Rule 13d-3 under the Securities Exchange Act
of 1934, as amended (the “Exchange Act”)) of certain shares of common stock of Flexion Therapeutics, Inc., a Delaware
corporation (the “Company”).

  

B.           Parent,
Purchaser and the Company are entering into an Agreement and Plan of Merger dated on or about the date hereof (the “Merger Agreement”)
which provides, among other things, for Purchaser to commence a cash tender offer (the “Offer”) to acquire all of the
outstanding shares of Company Common Stock, par value $0.001 per share, of the Company (the “Company Shares”) and following
the consummation of the Offer, the merger of Purchaser with and into the Company, with the Company continuing as the Surviving Corporation
and as a wholly owned subsidiary of Parent (the “Merger”), upon the terms and subject to the conditions set forth in
the Merger Agreement.

 

C.            As
a condition to the willingness of Parent and Purchaser to enter into the Merger Agreement and as an inducement in consideration therefor,
Stockholder has agreed to enter into this Agreement and tender and vote Stockholder’s Subject Securities (as defined below) as described
herein.

 

AGREEMENT

  

The parties to this Agreement,
intending to be legally bound, agree as follows:

 

	SECTION 1.	CERTAIN DEFINITIONS

 

For purposes of this Agreement:

 

(a)            Capitalized
terms used but not defined herein shall have the respective meanings assigned to those terms in the Merger Agreement.

  

(b)          “Contract”
means any note, bond, mortgage, indenture, lease, license, permit, contract, commitment, arrangement, understanding, agreement or other
instrument or obligations of any kind, including, any voting agreement, proxy arrangement, pledge agreement, stockholder agreement or
voting trust, to which Stockholder is a party or by which the Subject Securities are bound.

  

(c)          “Expiration
Date” means the earliest to occur, without any notice or other action by any Person, of (i) the valid termination of the
Merger Agreement in accordance with its terms, (ii) the Effective Time, or (iii) the entry without the prior written consent
of Stockholder into any amendment or modification to the Merger Agreement or any waiver of any of the Company’s rights under the
Merger Agreement, in each case, that results in a decrease in, or a change in the form of, the Offer Price.

  

     

     

    

 

(d)           “Lien”
means any lien, pledge, hypothecation, security interest, option, right of first refusal, proxy, voting trust or agreement, or other similar
encumbrance on the Subject Securities (other than (i) as created by this Agreement, or (ii) restrictions on transfer under the
Securities Act of 1933, as amended).

 

(e)            Stockholder
is deemed to “Own” or to have acquired “Ownership” of a security if Stockholder (i) is the
record owner of such security; or (ii) is the “beneficial owner” (within the meaning of Rule 13d-3 under the Exchange
Act) of such security.

 

(f)            “Subject
Securities” means (i) all Company Shares Owned by Stockholder as of the date hereof and (ii) all additional Company
Shares of which Stockholder acquires Ownership during the Support Period; provided that Company Shares that are automatically purchased
under the Company’s 2013 Employee Stock Purchase Plan within ten (10) Business Days prior to the Closing shall not be Subject
Securities. For the avoidance of doubt, Company Options and Company RSUs beneficially owned by Stockholder shall not be considered Subject
Securities, and Company Shares issued upon the exercise of a Company Option or the settlement of a Company RSU during the Support Period
shall be Subject Securities.

  

(g)            “Support
Period” means the period commencing on (and including) the date of this Agreement and ending on (and including) the Expiration
Date.

 

(h)            A
Person is deemed to have effected a “Transfer” of a security if such Person directly or indirectly: (i) sells,
pledges, gifts, hedges, encumbers, grants a Lien on or an option with respect to, enters into any derivative arrangement with respect
thereto, transfers or disposes of such security or any interest in such security or right therein to any Person other than Parent or Purchaser;
(ii) enters into an agreement or commitment contemplating the possible sale of, pledge of, gift, hedge, encumbrance or Lien of, grant
of an option with respect to, a derivative arrangement, transfer of or disposition of such security or any interest or right therein to
any Person other than Parent or Purchaser; or (iii) reduces such Person’s beneficial ownership of or interest in or risk relating
to such security or enters into a derivative arrangement with respect to such security.

 

	SECTION 2.	TRANSFER OF SUBJECT SECURITIES AND VOTING RIGHTS

 

2.1            Restriction
on Transfer of Subject Securities. Subject to Section 2.3 below, during the Support Period, Stockholder shall not cause
or permit any Transfer of any of the Subject Securities to be effected. Without limiting the generality of the foregoing, during the Support
Period, Stockholder shall not tender, agree to tender or permit to be tendered any of the Subject Securities in response to or otherwise
in connection with any tender or exchange offer other than the Offer.

 

    2 

     

    

 

2.2            Restriction
on Transfer of Voting Rights. During the Support Period, Stockholder shall ensure that: (a) none of the Subject Securities is
deposited or otherwise transferred into a voting trust or any voting agreement or arrangement is entered into with respect to the Subject
Securities (other than this Agreement); (b) no proxy, power-of-attorney, consent right or other authorization is granted, and no
voting agreement or similar agreement is entered into, with respect to any of the Subject Securities (other than this Agreement); and
(c) no action is taken or permitted that would in any way restrict, limit or interfere with the performance of Stockholder’s
obligations hereunder or otherwise make any representation or warranty of Stockholder herein untrue or incorrect.

  

2.3          Permitted
Transfers. Section 2.1 above shall not prohibit a Transfer of Subject Securities by Stockholder: (a) if Stockholder
is an individual (i) to any member of Stockholder’s immediate family, or to a trust for the benefit of Stockholder or any member
of Stockholder’s immediate family, or otherwise for estate planning purposes, or (ii) by
will or under the laws of intestacy upon the death of Stockholder; (b) make Transfers or dispositions not involving a change in beneficial
ownership; (c) if Stockholder is a trust, to any beneficiary of Stockholder or the estate of any such beneficiary; (d) by operation
of law or to a charitable organization qualified under Section 501(c)(3) of the Code; (e) by exercise of a Company Option
(including a net or cashless exercise of such Company Option to purchase Company Shares); (f) to the Company to cover tax withholding
obligations of Stockholder in connection with any option exercise or the vesting of any restricted stock or restricted stock unit award,
provided that the underlying Subject Securities shall continue to be subject to the restrictions on transfer set forth in this Agreement;
or (g) pursuant to the Company’s 10b5-1 Plan up to that number of Subject Securities as permitted to be sold under such 10b5-1
Plan; provided, however, that a Transfer referred to in clauses “(a)” through “(d)” of this sentence
shall be permitted only if (A) all of the representations and warranties in this Agreement
with respect to Stockholder would be true and correct upon such Transfer, (B) as a precondition to such Transfer, the transferee
agrees in a written document, reasonably satisfactory in form and substance to Parent, to be bound by all of the terms of this Agreement,
and (C) such transfer occurs no later than three (3) Business Days prior to the Expiration Date.

  

	SECTION 3.	TENDER OF SUBJECT SECURITIES

 

3.1            Tender
of Subject Securities. Until the Expiration Date, Stockholder hereby agrees, subject to Section 3.3, to tender the Subject
Securities free and clear of all Liens, or cause such Subject Securities to be tendered, into the Offer no later than the tenth (10th)
Business Day following the receipt by Stockholder of the Offer Documents (collectively, the “Initial Tender Shares”).
If Stockholder acquires additional Subject Securities after the date hereof and during the Support Period, Stockholder shall tender or
cause to be tendered such Subject Securities on or before the earlier of (a) five (5) Business Days after such acquisition,
and (b) one (1) Business Day prior to the Expiration Date (the “Additional Tender Shares”, and together with
the Initial Tender Shares, the “Tender Shares”). Until the Expiration Date, Stockholder will not withdraw the Tender
Shares, or cause the Tender Shares to be withdrawn, from the Offer. Stockholder shall notify Parent as promptly as reasonably practicable
in writing of the number of any additional shares of Company Shares which Stockholder acquires beneficial or record ownership after the
date hereof and during the Support Period.

 

    3 

     

    

 

3.2            Return
of Subject Securities. If (a) the Offer is terminated or withdrawn by Parent or Purchaser, or (b) the Expiration Date occurs
prior to the purchase of the Subject Securities in the Offer, Parent and Purchaser shall promptly direct any depository acting on behalf
of Parent and Purchaser to return, all Tender Shares to Stockholder.

 

3.3           No
Requirement to Exercise. Notwithstanding anything in this Agreement to the contrary, nothing herein shall require Stockholder to exercise
any Company Option or other equity award or require any Stockholder to purchase any Company Shares, and nothing herein shall prohibit
Stockholder from exercising any Company Option or other equity award or warrant held by Stockholder in accordance with the applicable
plan, award grant agreement(s), and/or other agreements(s) or document(s) evidencing such Company Option or other equity award
or warrant, as applicable.

 

	SECTION 4.	VOTING OF COMPANY SHARES

  

4.1           Voting
Covenant. During the Support Period, Stockholder hereby irrevocably and unconditionally agrees that, at
any annual or special meeting of the stockholders of the Company, however called, including any adjournment or postponement thereof, and
in connection with any action proposed to be taken by written consent of the stockholders of the Company, Stockholder shall, in each case
to the fullest extent that such Subject Securities are entitled to be voted therein: (a) appear at each such meeting or otherwise
cause all such Subject Securities to be counted as present thereat for purposes of determining a quorum; and (b) be present (in person
or by proxy) and vote (or cause to be voted), or deliver (or cause to be delivered) a written consent with respect to, all of the Subject
Securities, and unless otherwise directed in writing by Parent:

  

(a)            in
favor of (i) the Merger, the execution and delivery by the Company of the Merger Agreement and the adoption and approval of the Merger
Agreement and the terms thereof, and (ii) each of the other Transactions;

 

(b)            against
any action or agreement which is intended or would reasonably be expected to impede, delay, postpone, interfere with, nullify, prevent
or adversely affect in any material respect the Merger or any of the other Transactions or this Agreement, including (i) any proposal
of any Person (other than Parent and Purchaser) to acquire the Company or all or substantially all of the assets thereof or to engage
in any other similar extraordinary corporate transaction, (ii) any amendment to the certificate of incorporation or bylaws of the
Company, (iii) any material change to the capitalization of the Company, (iv) any change in a majority of the directors of the
Company Board and (v) any action, proposal, or agreement that would reasonably be expected to result in the any breach of any covenant,
representation or warranty or any other obligation or agreement under the Merger Agreement or this Agreement; and

 

(c)            against
any Acquisition Proposal and any action in furtherance of any Acquisition Proposal.

 

During the Support Period, Stockholder
shall not enter into any agreement or understanding with any Person to vote or give instructions in a manner inconsistent with clauses
 “(a)”, “(b)” or “(c)” of this Section 4.1.

 

    4 

     

    

 

4.2            Further
Assurances. Stockholder shall not enter into any tender, voting or other such agreement, or grant a proxy or power of attorney, with
respect to any of the Subject Securities that is inconsistent with this Agreement or otherwise take any other action with respect to any
of the Subject Securities that would restrict, limit or interfere with the performance of any of Stockholder’s obligations hereunder.

  

	SECTION 5. 	WAIVER OF APPRAISAL RIGHTS

 

5.1            During
the term of this Agreement, Stockholder hereby (a) irrevocably and unconditionally waives, and agrees not to exercise or assert,
on its own behalf or on behalf of any other holder of Company Shares, any rights of appraisal, any dissenters’ rights or any similar
rights relating to the Merger that Stockholder may have by virtue of, or with respect to, any Subject Securities and (b) agrees not
to commence or join in and agrees to use commercially reasonable efforts to take all actions necessary to opt out of, any class in any
class action with respect to, any claim, derivative or otherwise, against Parent, Purchaser or the Company or any of their respective
successors that challenges the validity of, or seeks to enjoin, any provision of this Agreement or alleges breach or any fiduciary duty
of any person in connection with the negotiation and entry into the Merger Agreement.

 

	SECTION 6.	REPRESENTATIONS AND WARRANTIES OF STOCKHOLDER

 

Stockholder hereby represents
and warrants to each of Parent and Purchaser as follows:

  

6.1            Authorization, etc.
Stockholder has the authority and legal capacity to execute and deliver this Agreement and to perform Stockholder’s obligations
hereunder. This Agreement has been duly authorized, executed and delivered by Stockholder and, assuming due authorization, execution and
delivery by Parent and Purchaser, constitutes a legal, valid and binding obligation of Stockholder, enforceable against Stockholder in
accordance with its terms, except as enforcement thereof may be limited by (i) Laws of general application relating to bankruptcy,
insolvency and the relief of debtors and (ii) rules of law governing specific performance, injunctive relief and other equitable
remedies. If Stockholder is a corporation, then Stockholder is a corporation duly organized, validly existing and in good standing under
the laws of the jurisdiction in which it was organized. If Stockholder is a general or limited partnership, then Stockholder is a partnership
duly organized, validly existing and in good standing under the laws of the jurisdiction in which it was organized. If Stockholder is
married, and any of the Subject Securities constitute community property or otherwise need spousal or other approval for this Agreement
to be legal, valid and binding, this Agreement has been duly executed and delivered by Stockholder’s spouse and, assuming due authorization,
execution and delivery by Parent and Purchaser, is enforceable against Stockholder’s spouse in accordance with its terms, except
as enforcement thereof may be limited by (x) Laws of general application relating to bankruptcy, insolvency and the relief of debtors
and (y) rules of law governing specific performance, injunctive relief and other equitable remedies.

 

6.2            No
Conflicts or Consents.

 

(a)           The
execution and delivery of this Agreement by Stockholder does not, and the performance of this Agreement by Stockholder will not: (a) assuming
the compliance of each of the Company, Parent and Purchaser, with all applicable Antitrust Laws, conflict with or violate any Law applicable
to Stockholder or by which Stockholder or any of Stockholder’s properties is or may be bound; (b) if Stockholder is not an
individual, violate, contravene or conflict with or result in any breach of any provision of the certificate of incorporation or bylaws
(or other similar governing documents) of Stockholder; or (c) result in or constitute (with or without notice or lapse of time) any
material breach of or material default under, or give to any other Person (with or without notice or lapse of time) any right of termination,
amendment, acceleration or cancellation of, or result (with or without notice or lapse of time) in the creation of any Lien on any of
the Subject Securities pursuant to, any Contract to which Stockholder is a party or by which Stockholder or any of Stockholder’s
Affiliates or properties is or may be bound or affected, except, in each case, for any conflict, violation, breach, default or right which
would not adversely affect in any material respect the ability of Stockholder to perform its obligations hereunder.

 

    5 

     

    

 

(b)            The
execution and delivery of this Agreement by Stockholder does not, and the performance of this Agreement by Stockholder will not, require
any filing with or notification of, nor any permit, authorization, consent or approval of, any Person, other than under any applicable
Antitrust Laws or where the failure to make such filings or obtain such permits, authorizations, consents or approvals would not, individually
or in the aggregate, prevent or materially delay the performance by Stockholder of any of its obligations under this Agreement. Assuming
the compliance of each of the Company, Parent and Purchaser with all applicable Antitrust Laws, no consent or notification of, or registration,
declaration or filing with, any Governmental Body is required to be obtained or made by or with respect to Stockholder in connection with
the execution, delivery or performance of this Agreement or the consummation of the transactions contemplated hereby, other than such
reports under Sections 13(d) and 16 of the Exchange Act as may be required in connection with this Agreement, or where the failure
to obtain such consents or make such registrations, declarations or filings would not adversely affect in any material respect the ability
of Stockholder to perform its obligations hereunder.

  

6.3          Title
to Company Shares. Stockholder (a) owns, free and clear of any Lien (other than Liens that would not adversely affect in any
material respect the ability of Stockholder to perform Stockholder’s obligations hereunder), the Subject Securities set forth opposite
Stockholder’s name on Exhibit A to this Agreement, and (b) except as set forth in Exhibit A hereto,
does not hold or have any ownership interest in any other Company Shares or any performance based stock awards, restricted stock, restricted
stock units, options (including any granted pursuant to the Company Equity Plan or the Company Prior Plan) or warrants to acquire Company
Shares, or other rights or securities convertible into or exercisable or exchangeable for Company Shares.

 

6.4            Legal
Proceedings. As of the date of this Agreement, there is no Legal Proceeding pending or, to the knowledge of Stockholder, threatened
against Stockholder or any of Stockholder's properties or assets that would reasonably be expected to impair the ability of Stockholder
to perform Stockholder’s obligations hereunder.

 

    6 

     

    

 

6.5         Merger
Agreement. Stockholder and its Representatives have reviewed and understand the terms of this Agreement and the Merger Agreement,
and Stockholder has had the opportunity to consult with Stockholder’s counsel in connection with this Agreement.

  

6.6            Voting
Power. Stockholder has full voting power with respect to all the Subject Securities,
and full power of disposition, full power to issue instructions with respect to the matters set forth herein and full power to agree to
all of the matters set forth in this Agreement, in each case with respect to all the Subject Securities. None of the Subject Securities
are subject to any stockholders’ agreement, proxy, voting trust or other agreement or arrangement with respect to the voting of
such Subject Securities, except as provided hereunder.

  

6.7            Reliance.
Stockholder understands and acknowledges that Parent and Purchaser are entering into the Merger
Agreement in reliance upon Stockholder’s execution, delivery and performance of this Agreement.

 

	SECTION 7.	REPRESENTATIONS AND WARRANTIES OF PARENT AND PURCHASER

 

Each of Parent and Purchaser
hereby, jointly and severally, represents and warrants to Stockholder as follows:

 

7.1            Authorization, etc.
Each of Parent and Purchaser has all necessary corporate power and authority to execute and deliver this Agreement and to perform its
obligations hereunder. This Agreement has been duly authorized, executed and delivered by each of Parent and Purchaser and, assuming due
authorization, execution and delivery by Stockholder, constitutes a legal, valid and binding obligation of Parent and Purchaser, enforceable
against Parent and Purchaser in accordance with their terms, subject to (a) Laws of general application relating to bankruptcy, insolvency
and the relief of debtors and (b) rules of law governing specific performance, injunctive relief and other equitable remedies.
Each of Parent and Purchaser is a corporation duly organized, validly existing and in good standing under the Laws of the jurisdiction
in which it was organized, except where the failure to be in good standing would not, individually or in the aggregate, prevent or materially
delay the performance by Parent or Purchaser of their obligations under this Agreement.

 

7.2            No
Conflicts or Consents. The execution and delivery of this Agreement by Parent and Purchaser does not, and the performance of this
Agreement by Parent and Purchaser and their respective Representatives will not: (a) conflict with or violate any Law or Order applicable
to Parent and Purchaser (or any of such Representatives); or (b) require any filing with, nor any permit, authorization, consent
or approval of, or require any consent of, or registration, declaration or filing with, any Governmental Body, other than (i) any
applicable requirements of the Exchange Act, Nasdaq, and the DGCL, (ii) as required by Antitrust Laws, (iii) as contemplated
by the Merger Agreement (including schedules thereto), and (iv) where the failure to obtain such consents or approvals or to make
such filings, would not, individually or in the aggregate, prevent or materially delay the performance by Parent or Purchaser of their
obligations under this Agreement.

 

    7 

     

    

 

	SECTION 8.	COVENANTS OF STOCKHOLDER

 

8.1            Stockholder
Information; Disclosure. Stockholder hereby consents to and authorizes the publication and disclosure by Parent, Purchaser and the
Company (including in the Schedule TO, the Schedule 14D-9 or any other publicly filed documents relating to the Merger, the Offer or the
Transactions) of: (a) Stockholder’s identity; (b) Stockholder’s ownership of the Subject Securities; and (c) the
nature of Stockholder’s commitments, arrangements and understandings under this Agreement (including filing this Agreement as an
exhibit to any publicly filed documents relating to the Merger, the Offer or the Transactions), and any other information that Parent,
Purchaser or the Company determines to be necessary in any SEC disclosure document in connection with the Offer, the Merger or the Transactions.
Stockholder further agrees as promptly as practicable to notify Parent, Purchaser and the Company of any required corrections with respect
to any written information supplied by Stockholder specifically for use in any such disclosure document.

 

8.2           Further
Assurances. From time to time and without additional consideration, Stockholder shall (at Parent’s sole expense) execute and
deliver, or cause to be executed and delivered, such additional transfers, assignments, endorsements, consents and other instruments,
and shall (at Parent’s sole expense) take such further actions, as Parent may reasonably request for the purpose of carrying out
and furthering the intent of this Agreement.

  

8.3            Stop
Transfer Order; Legends. Stockholder hereby agrees that it will not request that the Company register the Transfer of any certificated
or uncertificated interest representing any of the Subject Securities, unless such Transfer is made in compliance with this Agreement.
In furtherance of this Agreement, concurrently herewith, Stockholder shall, and hereby does authorize Parent to direct the Company or
its counsel to, notify the Company’s transfer agent that there is a stop transfer order with respect to all of the Subject Securities
(and that this Agreement places limits on the voting and transfer of such shares). The parties hereto agree that such stop transfer order
shall be removed and shall be of no further force and effect upon the Expiration Date.

 

8.4           Public
Announcement. Stockholder shall not, and shall cause its Representatives not to, directly or indirectly, issue any press release,
public announcement or make any other public statement or communication with respect to the transactions contemplated by this Agreement
or the Merger Agreement without the prior written consent (email sufficient) of Parent, except as may be required by applicable Law provided
that to the extent feasible, Stockholder shall notify Parent in advance of any public statement it intends to make without Parent approval
because disclosure is required by applicable Law.

  

8.5            Waiver
of Certain Actions. Stockholder hereby agrees not to commence or participate in, and to take all actions necessary to opt out of any
class in any class action with respect to, any claim, derivative or otherwise, against Parent, Purchaser or any of their respective successors
(a) challenging the validity of, or seeking to enjoin or delay the operation of, any provision of this Agreement or the Merger Agreement
(including any claim seeking to enjoin or delay the Expiration Date or the Closing) or (b) alleging a breach of any duty of the Company
Board in connection with the Merger Agreement, this Agreement or the transactions contemplated thereby or hereby.

 

    8 

     

    

 

	SECTION 9.	MISCELLANEOUS

 

9.1      Adjustments.
In the event that, between the date of this Agreement and the Effective Time, (a) the outstanding Shares are changed into a different
number or class of shares by reason of any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation
of shares, reclassification, recapitalization or other similar transaction, or (b) Stockholder shall become the beneficial owner
of any additional Company Shares, then the terms of this Agreement shall apply to the Company Shares held by Stockholder immediately following
the effectiveness of the events described in the aforementioned clause (a) or Stockholder becoming the beneficial owner thereof as
described in the aforementioned clause (b), as though, in either case, they were Subject Securities hereunder. In the event that Stockholder
shall become the beneficial owner of any other securities entitling the holder thereof to vote or give consent with respect to the matters
set forth in Section 4 hereof, then the terms of Section 4 hereof shall apply to such other securities as though
they were Subject Securities hereunder.

 

9.2      Survival
of Representations, Warranties and Agreements. All representations, warranties, covenants and agreements in this Agreement, and all
rights and remedies with respect thereto, shall not survive the Expiration Date.

 

9.3      Expenses.
Except as provided in Sections 4.2 and 8.2 hereof, all costs and expenses incurred in connection with the transactions contemplated
by this Agreement shall be paid by the party incurring such costs and expenses.

 

9.4      Notices.
All notices and other communications hereunder shall be in writing and shall be deemed to have been duly delivered and received hereunder
(a) one (1) Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight
courier service, (b) upon delivery in the case of delivery by hand, (c) if sent by email transmission prior to 6:00 p.m. recipient’s
local time, upon transmission (provided, no “bounce back” or similar message of non-delivery is received with respect thereto)
or (d) if sent by email transmission after 6:00 p.m. recipient’s local time and no “bounce back” or similar
message of non-delivery is received with respect thereto, the Business Day following the date of transmission; provided, that in
each case the notice or other communication is sent to the physical address or email address set forth beneath the name of such party
below (or to such other physical address or email address as such party shall have specified in a written notice given to the other parties):

 

if to Stockholder:

 

at the address set forth on the signature page hereof;

 

and if to Parent or Purchaser
(or following the Effective Time, the Company):

 

5401 West Kennedy Boulevard, Suite 890 

Tampa, Florida 33609 

Attention: Kristen Williams 

Email: Kristen.Williams@pacira.com

 

    9

     

    

 

with a copy to (which copy shall not
constitute notice):

 

Perkins Coie LLP 

1900 Sixteenth Street, Suite 1400 

Denver, Colorado 80202 

Attention: Jason Day; Jeffrey Beuche 

Email: JDay@perkinscoie.com; JBeuche@perkinscoie.com

 

9.5      Severability.
Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity
or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision
in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or
provision of this Agreement is invalid or unenforceable, the parties agree that the court making such determination shall have the power
to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that
is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this
Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior
sentence, the parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision
that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision.

 

9.6      Entire
Agreement; Counterparts. This Agreement and any other documents delivered by the parties in connection herewith constitute the entire
agreement and supersede all prior agreements and understandings, both written and oral, among or between any of the parties, with respect
to the subject matter hereof and thereof. This Agreement may be executed in several counterparts, each of which shall be deemed an original
and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise)
by PDF shall be sufficient to bind the parties to the terms and conditions of this Agreement.

 

9.7      Assignment;
Binding Effect. No party may assign (by merger, operation of Law or otherwise) either this Agreement or any of its rights, interests,
or obligations hereunder without the prior written approval of the other parties; provided, that each of Parent or Purchaser may
assign, in its sole discretion, any or all of its rights, interests and obligations under this Agreement to any one or more direct or
indirect wholly owned Subsidiaries of Parent without the consent of Stockholder; provided, however, that no such assignment
shall release Parent or Purchaser of any of its obligations under this Agreement or enlarge any obligation of Stockholder hereunder. Any
purported assignment in violation of this Agreement will be void ab initio.

 

9.8      Independence
of Obligations. The covenants and obligations of Stockholder set forth in this Agreement shall be construed as independent of any
other agreement or arrangement between Stockholder, on the one hand, and the Company or Parent, on the other. The existence of any claim
or cause of action by Stockholder against the Company or Parent shall not constitute a defense to the enforcement of any of such covenants
or obligations against Stockholder.

 

    10

     

    

 

9.9      Governing
Law.

 

(a)       This
Agreement shall be governed by, and construed in accordance with, the Laws of the State of Delaware, regardless of the Laws that might
otherwise govern under applicable principles of conflicts of laws thereof. Subject to Section 9.9(c), in any action or proceeding
arising out of or relating to this Agreement or the transactions contemplated hereby: (i) each of the parties irrevocably and unconditionally
consents and submits to the exclusive jurisdiction and venue of the Chancery Court of the State of Delaware and any state appellate court
therefrom or, if such court lacks subject matter jurisdiction, the United States District Court sitting in New Castle County in the State
of Delaware, (it being agreed that the consents to jurisdiction and venue set forth in this Section 9.9(a) shall not
constitute general consents to service of process in the State of Delaware and shall have no effect for any purpose except as provided
in this paragraph and shall not be deemed to confer rights on any Person other than the parties); and (ii) each of the parties irrevocably
consents to service of process by first class certified mail, return receipt requested, postage prepaid, to the address at which such
Party is to receive notice in accordance with Section 9.4. The parties agree that a final judgment in any such action or proceeding
shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by applicable Laws;
provided, however, that nothing in the foregoing shall restrict any party’s rights to seek any post-judgment relief
regarding, or any appeal from, such final trial court judgment.

 

(b)       The
parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy will occur in the
event that the parties do not perform their obligations under the provisions of this Agreement in accordance with its specified terms
or otherwise breach such provisions. Subject to the following sentence, the parties acknowledge and agree that (i) the parties shall
be entitled to seek an injunction or injunctions, specific performance, or other equitable relief, to prevent breaches or threatened breaches
of this Agreement and to enforce specifically the terms and provisions hereof in the courts described in Section 9.9(a) without
proof of damages or otherwise, this being in addition to any other remedy to which they are entitled under this Agreement, and (ii) the
right of specific performance is an integral part of the transactions contemplated hereby and without that right, neither the Company
nor Parent would have entered into this Agreement. Each of the parties agrees that it will not oppose the granting of an injunction, specific
performance and other equitable relief on the basis that the other parties have an adequate remedy at law or an award of specific performance
is not an appropriate remedy for any reason at law or equity. The Parties acknowledge and agree that any party seeking an injunction or
injunctions to prevent breaches or threatened breaches of this Agreement and to enforce specifically the terms and provisions of this
Agreement in accordance with this Section 9.9(b) shall not be required to provide any bond or other security in connection
with any such order or injunction.

 

(c)       EACH
OF THE PARTIES HERETO IRREVOCABLY WAIVES TO THE FULLEST EXTENT PERMISSIBLE UNDER THE LAW ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL
PROCEEDING BETWEEN THE PARTIES HERETO ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.

 

    11

     

    

 

9.10    Waiver.
No failure on the part of any party hereto to exercise any power, right, privilege or remedy under this Agreement, and no delay on
the part of such party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power,
right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or
further exercise thereof or of any other power, right, privilege or remedy. No party shall be deemed to have waived any claim arising
out of this Agreement, or any power, right, privilege or remedy under this Agreement, unless the waiver of such claim, power, right, privilege
or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of such party; and any such waiver shall
not be applicable or have any effect except in the specific instance in which it is given.

 

9.11    Termination.
This Agreement and all rights and obligations of the parties hereunder shall automatically terminate, and no party shall have any
rights or obligations hereunder, and this Agreement shall be revoked and become null and void on, and have no further effect as of the
Expiration Date. Nothing in this Section 9.11 shall relieve any party from any liability for any Willful Breach of this Agreement
occurring prior to the termination of this Agreement and the provisions of this Section 9 (other than Section 9.1)
shall survive any termination of this Agreement. For the avoidance of doubt, the representations and warranties herein shall not survive
the termination of this Agreement.

 

9.12    Directors
and Officers. Stockholder signs this Agreement solely in Stockholder’s capacity as a stockholder of the Company, and not in
Stockholder’s capacity as a director, officer or employee of the Company. Nothing in this Agreement shall be construed to prohibit
Stockholder or any of Stockholder’s Representatives who is an officer or member of the Company Board from taking any action (or
failure to act) in his or her capacity as an officer or member of the Company Board or from taking any action with respect to any Acquisition
Proposal solely in their capacity as such an officer or director or in the exercise of his or her fiduciary duties in his or her capacity
as director or officer of the Company, or prevent or be construed to create any obligation on the part of any director or officer of the
Company from taking any action in his or her capacity as such director or officer, and no action taken solely in any such capacity as
an officer or director of the Company shall be deemed to constitute a breach of this Agreement.

 

9.13    Construction.

 

(a)       For
purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the masculine
gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter
gender shall include masculine and feminine genders.

 

(b)       The
parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting party shall not
be applied in the construction or interpretation of this Agreement.

 

(c)       As
used in this Agreement, the words “include” and “including,” and variations thereof, shall not be deemed to be
terms of limitation, but rather shall be deemed to be followed by the words “without limitation.” The words “hereof”,
 “herein” and “hereunder” and words of like import used in this Agreement, unless otherwise stated, shall refer
to this Agreement as a whole and not to any particular provision of this Agreement.

 

    12

     

    

 

(d)       Unless
otherwise indicated all references in this Agreement to “Sections” and “Exhibits” are intended to refer to Sections
of this Agreement and Exhibits to this Agreement, as applicable.

 

(e)       The
headings set forth in this Agreement are for convenience of reference purposes only and shall not affect or be deemed to effect in any
way the meaning or interpretation of this Agreement or any term or provision hereof.

 

(f)        References
to “$” refer to United States dollars unless otherwise noted.

 

9.14    No
Ownership Interest. All rights, ownership and economic benefits of and relating to the Subject Securities at a given time shall remain
vested in and belong to Stockholder as of such time, and neither Parent nor Purchaser shall have any authority to exercise any power or
authority to direct Stockholder in the voting of any of the Subject Securities, except as otherwise specifically provided herein.

 

9.15    No
Agreement Until Executed. This Agreement shall not be effective unless and until (i) the Merger Agreement is executed by all
parties thereto and (ii) this Agreement is executed by all parties hereto.

 

9.16    Amendments
and Waivers. Any provision of this Agreement may be amended or waived if such amendment or waiver is in writing and is signed, (i) in
the case of an amendment, by each of (x) Parent and the Purchaser, on the one hand, and (y) Stockholder, on the other hand,
or (ii) in the case of a waiver, by each party against whom such waiver is to be effective. No failure or delay by any party in exercising
any right, power or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any
other or further exercise thereof or the exercise of any other right, power or privilege.

 

[Remainder of page intentionally
left blank]

 

    13

     

    

 

In
Witness Whereof, each of Parent, Purchaser and Stockholder has caused this Tender and Support Agreement to be executed as of the
date first written above.

 

	 	PACIRA
    BIOSCIENCES, INC.
	 	 
	 	By:	 
	 	Name: 	 
	 	Title:	 
	 	 
	 	OYSTER
    ACQUISITION COMPANY INC.
	 	 
	 	By:	 
	 	Name: 	 
	 	Title:	 

 

[Signature Page to
Tender and Support Agreement]

 

     

     

    

 

In
Witness Whereof, each of Parent, Purchaser and Stockholder has caused this Tender and Support Agreement to be executed as of the
date first written above.

 

	 	Stockholder
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Printed
    Name
	 	 
	 	Address:	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	Email:	 

 

[Signature
Page to Tender and Support Agreement]

 

     

     

    

 

Exhibit A

 

Subject
Securities, Company RSUs and Company Options

 

	
    Stockholder:
	 
	 	
     

	 	 	 
	 	 	Number of: 
	 	 	 
	Company Shares	 	 
	Shares Underlying Company RSUs	 	 
	Company OptionsEX-10.1

 Exhibit 10.1 
  

 
 October 5, 2021 
 Rita
I. Jain, M.D. 
 Dear Rita: 
 On behalf of ChemoCentryx, Inc.
(“ChemoCentryx” or the “Company”), I am pleased to offer you employment as Executive Vice President, Chief Medical Officer. In this position, you will report to Thomas Schall, President and Chief Executive Officer,
and will work from your Chicago, Illinois location while travelling regularly to ChemoCentryx headquarters in San Carlos, California (average one week or more per month). 

Compensation & Benefits 
 Your initial annual
base salary will be $525,000.00 less applicable deductions and withholdings, which will be paid semi-monthly in accordance to the Company’s normal payroll procedures. As an exempt employee, you will be required to work the Company’s normal
business hours and additional hours as required by the nature of your work assignments, and you will not be entitled to payment of overtime. You are also eligible for certain employee benefits available generally to employees of ChemoCentryx
pursuant to the terms of such benefit plans. You should note that ChemoCentryx may modify salaries, benefits, duties, titles, reporting relationships, and work locations from time to time at its discretion. 

You will be eligible to participate in the ChemoCentryx Corporate Bonus plan, and your target award opportunity is 50% of your gross annual salary in effect
during the bonus year (the “Annual Bonus”). Actual payment of the Annual Bonus will be based upon factors including, but not limited to, individual and Company performance and compliance with Company policies and procedures.
During your first partial year of employment, your Annual Bonus target amount will be prorated based on your date of hire. You must be an active ChemoCentryx employee in good standing (e.g. not subject to an active compliance
investigation, verbal counseling, any written warning, or a performance improvement plan) as of the date of any Annual Bonus is paid in order to earn the bonus. The Company will have the sole discretion to determine whether and to what extent the
applicable corporate and individual goals and other bonus criteria have been achieved, and the amount of any awarded Annual Bonus. 
 Subject to and
following approval by the Company’s Board of Directors (the “Board”) or a committee thereof, the Company shall grant you an option to purchase 45,000 shares of the Company’s common stock (subject to stock splits and
similar adjustments) with a per share exercise price equal to the per share fair market value of the Company’s common stock on the date of grant (as determined by the Board or a committee thereof as of the date of grant) (the
“Option”) pursuant to the Company’s 2012 Equity Incentive Plan (the “Plan”). The Option will be governed in full by the terms and conditions of the Plan and your individual grant agreement, including the
service-based vesting schedule and requirements set forth therein. 

  
 Page 1 of 6 

 Offer of Employment: Rita I. Jain, M.D. 

 

 Policies/Confidential Information 

As a condition of your employment you will abide by the Company’s policies and procedures, including but not limited to the policies set forth in the
Company’s Employee Handbook, as may be in effect from time to time. You will be required to sign an acknowledgement that you have read and will comply with the policies contained in the Employee Handbook. You also must read, sign, and comply
with the Company’s Employee Confidential Information and Inventions Assignment Agreement (the “Confidential Information Agreement”), attached here as Exhibit A. In your work for the Company, you are expected not
to make unauthorized use or disclosure of any confidential or proprietary information or materials, including trade secrets, of any former employer or other third party to whom you have an obligation of confidentiality. By signing this letter, you
represent that you are able to perform your job duties within these guidelines, and you are not in unauthorized possession of any confidential documents or other property of any former employer or other third party. You further represent that you
have disclosed to the Company in writing any agreement you may have with any third party (e.g., a former employer) which may conflict with or limit your ability to perform your duties to the Company. 

At-Will Employment; Severance 

ChemoCentryx is pleased about your joining and looks forward to a beneficial and fruitful relationship. Nevertheless, you should be aware that your employment
is not for a specified period of time, it is terminable at-will by either party. This means that you may terminate your employment with the Company at any time and for any reason whatsoever simply by notifying
us. Likewise, the Company may terminate your employment at any time, with or without Cause, and with or without advance notice, simply by notifying you. 

If, at any time, the Company terminates your employment for Cause (as defined in Exhibit C), or if either party terminates your employment as a
result of your death or disability, or you resign for any reason, you will receive your base salary accrued through your last day of employment, as well as any unused vacation (if applicable) accrued through your last day of employment. Under these
circumstances, you will not be entitled to any other form of compensation from the Company, including any severance benefits. 
 If, at any time other than
on or within 12 months following the effective date of a Change in Control (as defined in Exhibit C), the Company terminates your employment without Cause, and other than as a result of your death or disability, and provided such
termination constitutes a “separation from service” (as defined under Treasury Regulation Section 1.409A-1(h), without regard to any alternative definition thereunder, a “Separation from
Service”), then subject to your obligations below, you shall be entitled to receive the following severance benefits (collectively, the “Non-CIC Severance Benefits”): 

(i) a cash amount equal to twelve (12) months of your then current base salary, less all applicable withholdings and deductions, paid over
such twelve (12) month period, on the schedule described below (the “Salary Continuation”); 
 (ii) if you timely elect
continued coverage under COBRA for yourself and your covered dependents under the Company’s group health plans following such termination or resignation of employment, then the Company shall pay the COBRA premiums necessary to continue your
health insurance coverage in effect for yourself and your eligible dependents on the termination date until the earliest of (A) the close of the twelve (12) month period following the termination of your employment, (B) the expiration
of your eligibility for the continuation coverage under COBRA, or (C) the date when you become eligible for substantially equivalent health insurance coverage in connection with new employment or self-employment (such period from the
termination date through the earliest of (A) through (C), the “COBRA Payment Period”). If you become eligible for coverage under another employer’s group health plan or otherwise cease to be eligible for COBRA during the
period provided in this clause, you must immediately notify the Company of such event, and all payments and obligations under this clause shall cease; and 

(iii) acceleration of the service-based vesting of the Option and any other equity grants you may hold as of the date of termination, to the
extent then outstanding, unvested and, if applicable, unexercised or unsettled, as to the number of shares subject to such equity grants that would have vested in accordance with the applicable service-based vesting schedule as if you had been in
service for an additional twelve (12) months as of your termination date (based upon full months of service). 

  
 Page 2 of 6 

 Offer of Employment: Rita I. Jain, M.D. 

 

 If, (1) at any time on or within 12 months following the effective date of a Change in Control (as
defined in Exhibit C), (2) (i) the Company terminates your employment without Cause, and other than as a result of your death or disability, or (ii) you terminate your employment with the Company for Good Reason (as defined in
Exhibit C), and (3) such termination constitutes a Separation from Service, then subject to your obligations below, you shall be entitled to receive the following severance benefits (collectively, the “CIC Severance
Benefits” and together with the Non-CIC Severance Benefits, the “Severance Benefits”): 

(i) a lump sum cash payment consisting of an amount equal to twelve (12) months of your then current base salary, less all applicable
withholdings and deductions (the “Lump Sum Salary Payment”); 
 (ii) a lump sum cash payment consisting of an amount equal
to your target Annual Bonus, with such bonus determined assuming all applicable performance objectives were obtained at target levels for the applicable year (the “Lump Sum Bonus Payment”); 

(iii) payment of your COBRA premiums as described above during the COBRA Payment Period, subject to the terms set forth above; and 

(iv) acceleration of the service-based vesting of the Option and any other equity grants you may hold as of the date of termination, to the
extent then outstanding, unvested and, if applicable, unexercised or unsettled, such that you will be deemed fully vested as to the service-based vesting requirement thereof as of your termination date. 

Notwithstanding the foregoing, if any of the Company’s applicable health benefits are self-funded as of the date of your Separation from Service or the
Company cannot provide the foregoing COBRA benefits in a manner that is compliant with applicable law, then, instead of providing the COBRA premiums in the manner described in either clause (ii) of the
Non-CIC Severance Benefits or clause (iii) of the CIC Severance Benefits, the Company will instead pay to you the applicable amount as a taxable monthly payment for the COBRA Payment Period (or any
remaining portion thereof). You will be solely responsible for all matters relating to continuation of coverage under COBRA, including, without limitation, the election of such coverage and, except to the extent the Company pays COBRA premiums on
your behalf, the timely payment of premiums. 
 Your receipt of any such Severance Benefits is conditioned upon (a) your continuing to comply with your
obligations under your Confidential Information Agreement; and (b) your delivering to the Company an effective, general release of claims in favor of the Company in a form acceptable to the Company (the “Release”) within 60
days following your termination date. The Salary Continuation, if applicable, will be paid in equal installments on the Company’s regular payroll schedule and will be subject to applicable tax withholdings; provided, however, that no payments
will be made prior to the date on which the Release is effective. Within 60 days following your Separation from Service (but in no event later than March 15 of the year following the year in which the Separation from Service occurred), and
subject to the Release becoming effective on or prior to such date, the Company will pay you in a lump sum the Salary Continuation or the Lump Sum Salary Payment and Lump Sum Bonus Payment, as applicable, and other applicable Severance Benefits that
you would have received on or prior to such date under the original schedule but for the delay while waiting for the effectiveness of the Release, with the balance of the Salary Continuation, if applicable, and other applicable Severance Benefits
being paid as originally scheduled. In no event will you be entitled to both the Non-CIC Severance Benefits and the CIC Severance Benefits. For the avoidance of doubt, the vesting acceleration set forth in the
Severance Benefits will not apply to any equity award(s) to the extent vesting thereof is subject to the satisfaction of any performance-based metrics (other than remaining in continuous service with the Company or certain of its affiliates). Any
vesting acceleration and other vesting terms of any such performance-based equity awards, if any, will be governed by the terms of the equity plan under which they are granted and the terms and conditions set forth in the award agreements governing
such awards. 
 Additional Tax Matters 
 The provisions
relating to Code Section 409A and Code Section 280G each as defined and set forth in Exhibit C hereto are incorporated herein by reference and form part of this letter. 

  
 Page 3 of 6 

 Offer of Employment: Rita I. Jain, M.D. 

 

 Dispute Resolution 

To aid in the rapid and economical resolution of disputes that may arise between us, you and the Company agree that any and all disputes, claims, or demands in
any way arising from or relating to this offer letter agreement, your employment with the Company, or the termination of your employment with the Company, including but not limited to any statutory claims, shall be resolved, to the fullest extent
permitted by law, pursuant to the Federal Arbitration Act, 9 U.S.C. § 1-16, by final, binding and confidential arbitration in San Francisco, California conducted before a single arbitrator by JAMS, Inc.
(“JAMS”) or its successor, under the then-applicable JAMS rules. You acknowledge that by agreeing to this arbitration procedure, you and the Company waive the right to resolve any such dispute, claim or demand through a trial by
jury or judge or by administrative proceeding. In addition, all claims, disputes, or causes of action under this section, whether by you or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant)
or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity. The arbitrator may not consolidate the claims of more than one person or entity, and may not preside over
any form of representative or class proceeding. To the extent that the preceding sentences regarding class claims or proceedings are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a
class shall proceed in a court of law rather than by arbitration. This paragraph shall not apply to any action or claim that cannot be subject to mandatory arbitration as a matter of law, including, without limitation, claims brought pursuant to the
California Private Attorneys General Act of 2004, as amended, the California Fair Employment and Housing Act, as amended, and the California Labor Code, as amended, to the extent such claims are not permitted by applicable law to be submitted to
mandatory arbitration and are not preempted by the Federal Arbitration Act (collectively, the “Excluded Claims”). In the event you intend to bring multiple claims, including one of the Excluded Claims listed above, the Excluded
Claims may be publicly filed with a court, while any other claims will remain subject to mandatory arbitration. You will have the right to be represented by legal counsel at any arbitration proceeding. Questions of whether a claim is subject to
arbitration under this agreement shall be decided by the arbitrator. Likewise, procedural questions which grow out of the dispute and bear on the final disposition are also matters for the arbitrator. The arbitrator shall: (a) have the
authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be available under applicable law in a court proceeding; and (b) issue a written statement signed by the arbitrator regarding
the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator’s essential findings and conclusions on which the award is based. The arbitrator shall be authorized to award all
relief that you or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS’ arbitration fees. Nothing in this offer letter is intended to prevent either you or the Company from obtaining injunctive relief in
court to prevent irreparable harm pending the conclusion of any arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction. 

Miscellaneous 
 Federal immigration law requires that we
verify your right to work legally in the United States and your employment at ChemoCentryx is contingent upon satisfactory proof of your right to work legally in the United States. On the back of the Form I-9,
you will find ‘Lists of Acceptable Documents’ that both identify and establish employment eligibility. Please bring in either one document from List A or one document from list B and list C on your first day of work. These document(s) must
be provided to us no later than three business days after your date of hire or your employment relationship with ChemoCentryx may be terminated. 

ChemoCentryx also participates in E-Verify. All newly-hired employees are queried through this electronic system
established by the Department of Homeland Security (DHS) and the Social Security Administration (SSA) to verify their identity and employment eligibility. If you will not be present at a ChemoCentryx office location on your first day of employment,
please contact Human Resources for instructions. 

  
 Page 4 of 6 

 Offer of Employment: Rita I. Jain, M.D. 

 

 This letter, together with its exhibits, forms your complete and exclusive agreement with the Company
concerning the subject matter hereof. The employment terms in this letter supersede any other representations or agreements made to you by any party, whether oral or written. The terms of this agreement cannot be changed (except with respect to
those changes expressly reserved to the Company’s discretion in this letter) without a written agreement signed by you and a duly authorized officer of the Company. This agreement is to be governed by the laws of the state of California without
reference to conflicts of law principles. In case any provision contained in this agreement shall, for any reason, be held invalid or unenforceable in any respect, such invalidity or unenforceability shall not affect the other provisions of this
agreement, and such provision will be reformed, construed and enforced so as to render it valid and enforceable consistent with the general intent of the parties insofar as possible under applicable law. With respect to the enforcement of this
agreement, no waiver of any right hereunder shall be effective unless it is in writing. For purposes of construction of this agreement, any ambiguity shall not be construed against either party as the drafter. This agreement may be executed in more
than one counterpart, and signatures transmitted via facsimile or PDF shall be deemed equivalent to originals. 
 ChemoCentryx requires all staff in the
United States to be fully vaccinated (FDA approved vaccines or vaccines that have FDA Emergency Use Authorization) from COVID-19 as a condition of employment. In accordance with applicable
laws, ChemoCentryx will provide reasonable accommodations to staff members who qualify on the basis of a medical reason or a sincerely held religious belief, practice, or observance.

Your employment at ChemoCentryx is contingent upon satisfactory completion of professional references, drug test and background checks. You agree to assist as
needed and to complete any documentation at the Company’s request to meet these conditions. If you wish to accept employment at ChemoCentryx under the terms contained above, please sign and date this letter and the Confidential Information
Agreement by October 8, 2021, and return to the Senior Vice President, Human Resources. This offer of employment will terminate if it is not accepted, signed, and returned by this date. 

We look forward to you joining ChemoCentryx and to a productive and enjoyable work relationship. 

Very best regards, 
  

	
	 /s/ Kari Leetch

	Kari E. Leetch
	Senior Vice President, Human Resources

  
 Page 5 of 6 

 Offer of Employment: Rita I. Jain, M.D. 

 

					
	Understood and Accepted:	 		  	
			
	 /s/ Rita Jain
	 	        	  	 10/5/2021

	Employee Signature	 		  	    Date
			
		 		  	     10/5/2021

		 		  	    Start Date

 Enclosures 
 Exhibit A
– Employee Confidential Information and Inventions Assignment Agreement 
 Exhibit B – State Specific Notifications/Modification (As Applicable)

 Exhibit C – Definitions and Additional Tax Matters 

  
 Page 6 of 6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}]]